Amgen (AMGN) Tops Q2 EPS by 51c; raises guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $5.00, $0.51 better than the analyst estimate of $4.49. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.67 billion.

GUIDANCE:

Amgen sees FY2023 EPS of $17.80-$18.80, versus the consensus of $17.75. Amgen sees FY2023 revenue of $26.6-27.4 billion, versus the consensus of $26.56 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• FTC files amicus brief challenging Amgen's Enbrel patent acquisition
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance